Sarepta Therapeutics (SRPT) Cost of Revenue (2017 - 2026)

Sarepta Therapeutics has reported Cost of Revenue for 10 years, with the latest figure at $108.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 20.93% year-over-year to $108.8 million; the trailing twelve-month figure through Mar 2026 stood at $810.8 million (up 99.66% YoY), and the FY2025 full-year result was $839.6 million, up 163.12% from the prior year.
• Cost of Revenue for Q1 2026 stood at $108.8 million, down from $398.7 million in the prior quarter.
• The five-year high for Cost of Revenue was $398.7 million in Q4 2025, with the low at $30.8 million in Q4 2022.
• Average Cost of Revenue over 5 years is $91.6 million, with a median of $44.5 million recorded in 2024.
• Year-over-year, Cost of Revenue soared 242.48% in 2025 and fell 20.93% in 2026.
• Tracing SRPT's Cost of Revenue over 5 years: stood at $30.8 million in 2022, then jumped by 43.43% to $44.2 million in 2023, then jumped by 199.49% to $132.3 million in 2024, then surged by 201.36% to $398.7 million in 2025, then slumped by 72.72% to $108.8 million in 2026.
• The last three Cost of Revenue figures came in at $108.8 million (Q1 2026), $398.7 million (Q4 2025), and $150.8 million (Q3 2025), per Business Quant data.

Peer Comparison